Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results, Misses Expectations By $0.24 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24), Zacks reports. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR traded down $0.20 during mid-day trading on Tuesday, reaching $3.97. 560,930 shares of the company traded hands, compared to its average volume of 493,528. The firm has a market cap of $216.87 million, a PE ratio of 5.59 and a beta of 0.99. Voyager Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $10.66. The stock has a fifty day simple moving average of $4.98 and a 200-day simple moving average of $5.89.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Wedbush reissued an “outperform” rating and set a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a research report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, March 3rd. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $5.73 target price on the stock. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.72.

Insider Buying and Selling at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.